Exact Sciences is committed to helping win the war on cancer through early detection.

Learn More

Cologuard: the first and only FDA approved stool DNA noninvasive colorectal cancer screening test.*

Learn More about Cologuard
*For average risk individuals only. Click the link above and talk to your doctor to see if Cologuard is right for you.

Latest News

Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

Gross margin expands to 65 percent during first quarter Revenue guidance raised to $195-205 million for 2017, from $170-180 million; Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000; 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent. MADISON, Wis., April 27, 2017 /PRNewswire/...Read more

CMS includes Cologuard in updated Medicare Advantage Star Ratings

    MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive...Read more


View updates on upcoming conference appearances, company news, financial reports and more.

Learn More

Exact Sciences Laboratories is dedicated to delivering the most accurate results and providing physicians and patients with world-class service.

Go To ExactLabs.com